GlassScriptPhysician profile
Lucy Greer Sorto
NPI 1366056764
$6,991.72
in general payments reported to CMS, 2019-2025
55 companies · $2,575 in 2025
The $2,575 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $628 · 2023: $1,869 · 2024: $1,920 · 2025: $2,575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,692 · Long Term Medical Supply Or Device Loan: $399 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,692.07 |
| Long Term Medical Supply Or Device Loan | $398.80 |
| Education | $272.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $636.23 | 2023-2025 | |
| Celgene Corporation | $456.94 | 2022-2025 | Reblozyl, Pomalyst, Breyanzi |
| Exelixis INC. | $427.24 | 2022-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $388.44 | 2023-2025 | Lynparza, Enhertu, Calquence |
| Abbvie INC. | $377.12 | 2022-2025 | |
| Janssen Biotech, INC. | $342.34 | 2022-2025 | Darzalex, Talvey, Imbruvica |
| Bayer Healthcare Pharmaceuticals INC. | $304.65 | 2022-2025 | |
| Astellas Pharma US INC | $286.49 | 2024-2025 | Padcev, Xtandi |
| Daiichi Sankyo INC. | $269.05 | 2022-2025 | Enhertu, Datroway |
| Incyte Corporation | $246.56 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Merck Sharp & Dohme LLC | $218.65 | 2022-2025 | Keytruda, Welireg, Keytruda Qlex |
| Eisai INC. | $213.59 | 2022-2025 | |
| Gilead Sciences, INC. | $209.64 | 2022-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $203.91 | 2023-2025 | Fruzaqla, Ninlaro, Iclusig |
| Pfizer INC. | $186.82 | 2022-2025 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $183.70 | 2022-2025 | Opdivo, Opdualag |
| Glaxosmithkline, LLC. | $177.06 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Genentech USA, INC. | $146.94 | 2022-2025 | Venclexta, Itovebi, Gavreto |
| Seagen INC. | $110.28 | 2022-2023 | Padcev, Adcetris |
| Myriad Genetic Laboratories, INC. | $110.07 | 2024 | Myrisk |
| Rigel Pharmaceuticals, INC. | $87.50 | 2022-2024 | Tavalisse, Rezlidhia |
| Adc Therapeutics America, INC. | $83.54 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $80.60 | 2023-2025 | Xpovio |
| Tempus Ai, INC | $80.29 | 2024-2025 | Xt Cdx |
| Tersera Therapeutics LLC | $75.77 | 2023-2025 | Zoladex, Xermelo |
| Amgen INC. | $72.23 | 2022-2023 | Lumakras, Kyprolis, Blincyto |
| Pharmaessentia USA Corporation | $66.53 | 2024-2025 | Besremi |
| Beone Medicines USA, INC. | $63.31 | 2025 | Brukinsa |
| Lilly USA, LLC | $59.95 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Stemline Therapeutics INC. | $59.50 | 2023-2024 | Orserdu |
| Adaptive Biotechnologies Corporation | $57.18 | 2024-2025 | Clonoseq |
| Puma Biotechnology, INC. | $55.76 | 2022-2024 | |
| Kite Pharma, INC. | $53.89 | 2025 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $53.14 | 2024 | Libtayo |
| Alexion Pharmaceuticals, INC. | $45.69 | 2024-2025 | Ultomiris |
| Sobi, INC | $42.46 | 2024 | |
| Agios Pharmaceuticals, INC. | $40.90 | 2022-2023 | Pyrukynd |
| G1 Therapeutics, INC. | $37.05 | 2023 | Cosela |
| Servier Pharmaceuticals LLC | $35.11 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $33.71 | 2022-2024 | |
| Genzyme Corporation | $32.27 | 2025 | |
| Cti Biopharma Corp. | $30.07 | 2023 | Vonjo |
| Pharmacyclics LLC, An Abbvie Company | $25.29 | 2023 | Imbruvica |
| Deciphera Pharmaceuticals INC. | $22.19 | 2025 | Romvimza, Qinlock |
| Pharmacosmos Therapeutics INC. | $20.97 | 2025 | Monoferric |
| Foundation Medicine, INC. | $20.74 | 2022 | |
| Morphosys, US INC. | $20.14 | 2023 | Monjuvi |
| Emd Serono, INC. | $18.67 | 2023 | Bavencio |
| Epizyme, INC. | $18.53 | 2023 | Tazverik |
| Taiho Oncology, INC. | $18.44 | 2022 | |
| Recordati_rare_diseases_inc. | $18.34 | 2023 | Sylvant |
| Genmab U.S., INC. | $18.27 | 2024 | Epkinly |
| Progenics Pharmaceuticals, INC. | $18.01 | 2025 | |
| Array Biopharma INC | $16.96 | 2025 | Mektovi, Braftovi, Tukysa |
| Acrotech Biopharma INC. | $13.00 | 2023 | Beleodaq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucy Sorto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.